Tuberous Sclerosis Complex (TSC1, TSC2)

Total Page:16

File Type:pdf, Size:1020Kb

Tuberous Sclerosis Complex (TSC1, TSC2) European Journal of Human Genetics (2014) 22, doi:10.1038/ejhg.2013.129 & 2014 Macmillan Publishers Limited All rights reserved 1018-4813/14 www.nature.com/ejhg CLINICAL UTILITY GENE CARD Clinical utility gene card for: Tuberous sclerosis complex (TSC1, TSC2) Karin Mayer*,1, Christa Fonatsch2, Katharina Wimmer3, Ans MW van den Ouweland4 and Anneke JA Maat-Kievit4 European Journal of Human Genetics (2014) 22, doi:10.1038/ejhg.2013.129; published online 12 June 2013 1. DISEASE CHARACTERISTICS For detection of chromosomal rearrangements, oligo and SNP 1.1 Name of the disease (synonyms) array analyses can be performed. An exception is a microdeletion, Tuberous sclerosis complex (TSC), Bourneville-Pringle disease. particularly a TSC2/PKD1 contiguous gene syndrome, which can be detected by FISH (fluorescence in situ hybridisation).2 1.2 OMIM# of the disease Next-generation sequencing approaches can also be used. 191100, 613254. 1.7 Analytical validation Bidirectional sequence analysis or other methods with a comparable 1.3 Name of the analysed genes or DNA/chromosome segments sensitivity as sequence analysis; confirmation of results by a second TSC1, TSC2. DNA extraction or a second method; confirmation of intragenic or larger chromosomal deletions by a second method, for example, 1.4 OMIM# of the gene(s) quantitative PCR, long-range PCR, and FISH. Variants of unknown 605284, 191092. significance should be further investigated at least by in silico analysis and, if possible, by segregation analysis. In some cases (especially for 1.5 Mutational spectrum some missense and splice site variants), it can be still unclear Missense, nonsense, and splice site mutations; insertions, deletions, whether these variants are disease-causing or rare neutral variants. genomic rearrangements, microdeletions, intragenic differences of Functional tests can be used to help resolve whether these variants gene dose/changes of copy number (duplications or deletions of one are likely to be disease-causing.3 Intronic variants, missense, or more exons). and synonymous changes that are suspected to affect RNA splicing Presently, more than 450 different disease-causing mutations are should be verified by investigating an RNA sample, applying known for TSC1 and more than 1300 for TSC2, respectively. The vast RT-PCR for example. majority (80%) of TSC1 mutations are truncating comprising frame- shift, nonsense, and splice mutations. Missense changes represent 1.8 Estimated frequency of the disease (incidence at birth (‘birth 17% and large genomic deletions are rare (3%). Truncating mutations prevalence’) or population prevalence) (65%) are also the most common mutation type in the TSC2 gene. In Birth incidence is estimated to be 1:6000.4 Numbers for prevalence contrast to the TSC1 gene, missense mutations (26%) and large range from 0.7 to 3.8 per 100 000 population in the United Kingdom5 genomic deletions (6%) occur substantially more frequently. Muta- assuming no differences in other ethnical groups. tions that have been published in the literature and mutations submitted without publication are available in the Tuberous sclerosis 1.9 If applicable, prevalence in the ethnic group of investigated 1 database. person Not applicable. 1.6 Analytical methods For detection of point mutations and small insertions/deletions: 1.10 Diagnostic setting complete analysis of all coding regions and neighbouring intron sequences (splice sites) in genomic DNA, by sequence analysis or Yes No. other techniques with a sensitivity comparable to sequence analysis. A. (Differential) diagnostics 2 & For detection of intragenic deletions and duplications with B. Predictive Testing 2 & differences of gene dose: analysis of both genes, for example, by C. Risk assessment in relatives 2 & MLPA (multiplex ligation dependent probe amplification) or quanti- D. Prenatal 2 & tative PCR. 1Center for Human Genetics and Laboratory Diagnostics, Department of Molecular Genetics, Dr. Klein, Dr. Rost and Colleagues, Martinsried, Germany; 2University Council, Medical University of Innsbruck, Innsbruck, Vienna, Austria; 3Division of Human Genetics, Department of Medical Genetics, Molecular and Clinical Pharmacology, Medical University Innsbruck, Innsbruck, Austria; 4Department Clinical Genetics, Erasmus Medical Center, Rotterdam, The Netherlands *Correspondence: Dr K Mayer, Center for Human Genetics and Laboratory Diagnostics, Department of Molecular Genetics, Dr. Klein, Dr. Rost and Colleagues, Lochhamer Street 29, D-82152 Martinsried, Germany. Tel: +49 89 895578 0; Fax: +49 89 895578 780; E-mail: [email protected] Clinical Utility Gene Card e2 Comment: As there is an almost 100% penetrance, clinical predictive value is Prenatal genetic testing including polar body analysis and pre- 100%. However, there may be highly variable clinical expressivity.16 implantation genetic testing is available for families with a known genetic cause of TSC. Caveat: (germline) mosaicism6 in one of the 2.6 Negative clinical predictive value parents of a patient if they both test negative for the constitutive (probability of not developing the disease if the test is negative) mutation, offer prenatal testing for new pregnancies, and offer to test Assume an increased risk based on family history for a non-affected other siblings of the patient. person. Allelic and locus heterogeneity may need to be considered. Index case in that family had been tested: 2. TEST CHARACTERISTICS If the pathogenic mutation is identified in the index patient and is tested negative in another family member, then the clinical predictive value for the family member is almost 100%. Genotype or disease A: True positives C: False negative Index case in that family had not been tested: B: False positives D: True negative 85%. This question arises in children who have no clinical Present Absent symptoms yet, or in adults with minimal clinical symptoms such that the diagnosis cannot be made by clinical criteria alone. Test Positive A B Sensitivity: A/(A þ C) 3. CLINICAL UTILITY Specificity: D/(D þ B) Negative C D Positive predictive value: A/(A þ B) 3.1 (Differential) diagnostics: The tested person is Negative predictive value: D/(C þ D) clinically affected (To be answered if in 1.10 ‘A’ was marked) 2.1 Analytical sensitivity 3.1.1 Can a diagnosis be made other than through a genetic test? (proportion of positive tests if the genotype is present) Assuming a prevalence of 90% for point mutations and of up to No & (continue with 3.1.4) 2 10% for intragenic deletions/duplications, microdeletions and rear- Yes 2 rangements, germline mutations will be detected in 80–85% of cases7 Clinically Imaging 2 if both genes are analysed by multiple methods, including a deletion/ Endoscopy & duplication screen. Rare splice mutations located deep in introns or Biochemistry & mutations affecting mRNA expression (for example in promoter Electrophysiology & regions) are not detected by current DNA-based diagnostics but can Other (please describe) Through clinical and imaging investigations, a 8 be identified with RNA-based methods. Additional mutations not definite diagnosis of TSC can be made if the detected by routine diagnostic methods like Sanger sequencing and diagnostic criteria are fulfilled. The diagnosis can MLPA may be identified applying next-generation sequencing be ‘probable’ or ‘possible’, owing to the variable 9,10 approaches. expressivity of the clinical signs, young age, or mosaicism. In the latter, a diagnosis may be arrived 2.2 Analytical specificity at if DNA for TSC testing of the tissue in question, (proportion of negative tests if the genotype is not present) in case of segmental or somatic mosaicism, is Nearly 100%. available through surgery or biopsy. Also with weak clinical manifestations (eg, only angiomyolipoma 2.3 Clinical sensitivity (AML) of the kidney or cortical tubers in the brain) (proportion of positive tests if the disease is present) the diagnosis of TSC requires the detection of a The clinical sensitivity can be dependent on variable factors such as causative mutation.17 If the diagnostic criteria for age or family history or incomplete clinical investigations performed. TSC are not definite in a parent or another first In such cases, a general statement should be given, even if a degree relative of an affected person with an quantification can only be made case by case. identified TSC mutation, mutation analysis can Clinical sensitivity reaches 70–85% if the diagnostic criteria of confirm the diagnosis and may guide genetic Roach11 are fulfilled (corresponding to ‘TSC definite’), depending on counselling. the application of one or more analytical methods.12–15 Because of variable clinical expressivity, lower sensitivities are expected in phenotypes corresponding to ‘TSC probable’ and ‘TSC possible’. 3.1.2 Describe the burden of alternative diagnostic methods to the 2.4 Clinical specificity patient (proportion of negative tests if the disease is not present) There is no extra burden of the alternative diagnostic methods to a The clinical specificity can be dependent on variable factors such as patient. When TSC is suspected in a patient, full clinical and imaging age or family history or number of clinical investigations performed. investigations are needed, to get insight into the clinical status of the In such cases, a general statement should be given, even if a patient and to guide further follow-up. Because of the variability of quantification can only be made case by case. TSC, investigation of different organ systems are needed,
Recommended publications
  • The Retinoblastoma Tumor-Suppressor Gene, the Exception That Proves the Rule
    Oncogene (2006) 25, 5233–5243 & 2006 Nature Publishing Group All rights reserved 0950-9232/06 $30.00 www.nature.com/onc REVIEW The retinoblastoma tumor-suppressor gene, the exception that proves the rule DW Goodrich Department of Pharmacology & Therapeutics, Roswell Park Cancer Institute, Buffalo, NY, USA The retinoblastoma tumor-suppressor gene (Rb1)is transmission of one mutationally inactivated Rb1 allele centrally important in cancer research. Mutational and loss of the remaining wild-type allele in somatic inactivation of Rb1 causes the pediatric cancer retino- retinal cells. Hence hereditary retinoblastoma typically blastoma, while deregulation ofthe pathway in which it has an earlier onset and a greater number of tumor foci functions is common in most types of human cancer. The than sporadic retinoblastoma where both Rb1 alleles Rb1-encoded protein (pRb) is well known as a general cell must be inactivated in somatic retinal cells. To this day, cycle regulator, and this activity is critical for pRb- Rb1 remains an exception among cancer-associated mediated tumor suppression. The main focus of this genes in that its mutation is apparently both necessary review, however, is on more recent evidence demonstrating and sufficient, or at least rate limiting, for the genesis of the existence ofadditional, cell type-specific pRb func- a human cancer. The simple genetics of retinoblastoma tions in cellular differentiation and survival. These has spawned the hope that a complete molecular additional functions are relevant to carcinogenesis sug- understanding of the Rb1-encoded protein (pRb) would gesting that the net effect of Rb1 loss on the behavior of lead to deeper insight into the processes of neoplastic resulting tumors is highly dependent on biological context.
    [Show full text]
  • Challenges in Clinicogenetic Correlations: One Gene – Many Phenotypes Francesca Magrinelli, MD,1,2,* Bettina Balint, MD,1,3 and Kailash P
    REVIEW CLINICAL PRACTICE Challenges in Clinicogenetic Correlations: One Gene – Many Phenotypes Francesca Magrinelli, MD,1,2,* Bettina Balint, MD,1,3 and Kailash P. Bhatia, MD, FRCP1,* ABSTRACT: Background:Background Progress in genetics – particularly the advent of next-generation sequencing (NGS) – has enabled an unparalleled gene discovery and revealed unmatched complexity of genotype– phenotype correlations in movement disorders. Among other things, it has emerged that mutations in one and the same gene can cause multiple, often markedly different phenotypes. Consequently, movement disorder specialists have increasingly experienced challenges in clinicogenetic correlations. Objectives:Objectives To deconstruct biological phenomena and mechanistic bases of phenotypic heterogeneity in monogenic movement disorders and neurodegenerative diseases. To discuss the evolving role of movement disorder specialists in reshaping disease phenotypes in the NGS era. Methods:Methods This scoping review details phenomena contributing to phenotypic heterogeneity and their underlying mechanisms. Results:Results Three phenomena contribute to phenotypic heterogeneity, namely incomplete penetrance, variable expressivity and pleiotropy. Their underlying mechanisms, which are often shared across phenomena and non- mutually exclusive, are not fully elucidated. They involve genetic factors (ie, different mutation types, dynamic mutations, somatic mosaicism, intragenic intra- and inter-allelic interactions, modifiers and epistatic genes, mitochondrial heteroplasmy),
    [Show full text]
  • Essential Genes and Their Role in Autism Spectrum Disorder
    University of Pennsylvania ScholarlyCommons Publicly Accessible Penn Dissertations 2017 Essential Genes And Their Role In Autism Spectrum Disorder Xiao Ji University of Pennsylvania, [email protected] Follow this and additional works at: https://repository.upenn.edu/edissertations Part of the Bioinformatics Commons, and the Genetics Commons Recommended Citation Ji, Xiao, "Essential Genes And Their Role In Autism Spectrum Disorder" (2017). Publicly Accessible Penn Dissertations. 2369. https://repository.upenn.edu/edissertations/2369 This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/2369 For more information, please contact [email protected]. Essential Genes And Their Role In Autism Spectrum Disorder Abstract Essential genes (EGs) play central roles in fundamental cellular processes and are required for the survival of an organism. EGs are enriched for human disease genes and are under strong purifying selection. This intolerance to deleterious mutations, commonly observed haploinsufficiency and the importance of EGs in pre- and postnatal development suggests a possible cumulative effect of deleterious variants in EGs on complex neurodevelopmental disorders. Autism spectrum disorder (ASD) is a heterogeneous, highly heritable neurodevelopmental syndrome characterized by impaired social interaction, communication and repetitive behavior. More and more genetic evidence points to a polygenic model of ASD and it is estimated that hundreds of genes contribute to ASD. The central question addressed in this dissertation is whether genes with a strong effect on survival and fitness (i.e. EGs) play a specific oler in ASD risk. I compiled a comprehensive catalog of 3,915 mammalian EGs by combining human orthologs of lethal genes in knockout mice and genes responsible for cell-based essentiality.
    [Show full text]
  • Molecular Biology and Applied Genetics
    MOLECULAR BIOLOGY AND APPLIED GENETICS FOR Medical Laboratory Technology Students Upgraded Lecture Note Series Mohammed Awole Adem Jimma University MOLECULAR BIOLOGY AND APPLIED GENETICS For Medical Laboratory Technician Students Lecture Note Series Mohammed Awole Adem Upgraded - 2006 In collaboration with The Carter Center (EPHTI) and The Federal Democratic Republic of Ethiopia Ministry of Education and Ministry of Health Jimma University PREFACE The problem faced today in the learning and teaching of Applied Genetics and Molecular Biology for laboratory technologists in universities, colleges andhealth institutions primarily from the unavailability of textbooks that focus on the needs of Ethiopian students. This lecture note has been prepared with the primary aim of alleviating the problems encountered in the teaching of Medical Applied Genetics and Molecular Biology course and in minimizing discrepancies prevailing among the different teaching and training health institutions. It can also be used in teaching any introductory course on medical Applied Genetics and Molecular Biology and as a reference material. This lecture note is specifically designed for medical laboratory technologists, and includes only those areas of molecular cell biology and Applied Genetics relevant to degree-level understanding of modern laboratory technology. Since genetics is prerequisite course to molecular biology, the lecture note starts with Genetics i followed by Molecular Biology. It provides students with molecular background to enable them to understand and critically analyze recent advances in laboratory sciences. Finally, it contains a glossary, which summarizes important terminologies used in the text. Each chapter begins by specific learning objectives and at the end of each chapter review questions are also included.
    [Show full text]
  • Advances in Autism Genetics: on the Threshold of a New Neurobiology
    REVIEWS Advances in autism genetics: on the threshold of a new neurobiology Brett S. Abrahams and Daniel H. Geschwind Abstract | Autism is a heterogeneous syndrome defined by impairments in three core domains: social interaction, language and range of interests. Recent work has led to the identification of several autism susceptibility genes and an increased appreciation of the contribution of de novo and inherited copy number variation. Promising strategies are also being applied to identify common genetic risk variants. Systems biology approaches, including array-based expression profiling, are poised to provide additional insights into this group of disorders, in which heterogeneity, both genetic and phenotypic, is emerging as a dominant theme. Gene association studies Autistic disorder is the most severe end of a group of into the ASDs. This work, in concert with important A set of methods that is used neurodevelopmental disorders referred to as autism technical advances, made it possible to carry out the to determine the correlation spectrum disorders (ASDs), all of which share the com- first candidate gene association studies and resequenc- (positive or negative) between mon feature of dysfunctional reciprocal social interac- ing efforts in the late 1990s. Whole-genome linkage a defined genetic variant and a studies phenotype of interest. tion. A meta-analysis of ASD prevalence rates suggests followed, and were used to identify additional that approximately 37 in 10,000 individuals are affected1. loci of potential interest. Although
    [Show full text]
  • An Overview of the Main Genetic, Epigenetic and Environmental Factors Involved in Autism Spectrum Disorder Focusing on Synaptic Activity
    International Journal of Molecular Sciences Review An Overview of the Main Genetic, Epigenetic and Environmental Factors Involved in Autism Spectrum Disorder Focusing on Synaptic Activity 1, 1, 1 2 Elena Masini y, Eleonora Loi y, Ana Florencia Vega-Benedetti , Marinella Carta , Giuseppe Doneddu 3, Roberta Fadda 4 and Patrizia Zavattari 1,* 1 Department of Biomedical Sciences, Unit of Biology and Genetics, University of Cagliari, 09042 Cagliari, Italy; [email protected] (E.M.); [email protected] (E.L.); [email protected] (A.F.V.-B.) 2 Center for Pervasive Developmental Disorders, Azienda Ospedaliera Brotzu, 09121 Cagliari, Italy; [email protected] 3 Centro per l’Autismo e Disturbi correlati (CADc), Nuovo Centro Fisioterapico Sardo, 09131 Cagliari, Italy; [email protected] 4 Department of Pedagogy, Psychology, Philosophy, University of Cagliari, 09123 Cagliari, Italy; [email protected] * Correspondence: [email protected] The authors contributed equally to this work. y Received: 30 September 2020; Accepted: 30 October 2020; Published: 5 November 2020 Abstract: Autism spectrum disorder (ASD) is a neurodevelopmental disorder that affects social interaction and communication, with restricted interests, activity and behaviors. ASD is highly familial, indicating that genetic background strongly contributes to the development of this condition. However, only a fraction of the total number of genes thought to be associated with the condition have been discovered. Moreover, other factors may play an important role in ASD onset. In fact, it has been shown that parental conditions and in utero and perinatal factors may contribute to ASD etiology. More recently, epigenetic changes, including DNA methylation and micro RNA alterations, have been associated with ASD and proposed as potential biomarkers.
    [Show full text]
  • Prb2/P130: a New Candidate for Retinoblastoma Tumor Formation
    Oncogene (2006) 25, 5333–5340 & 2006 Nature Publishing Group All rights reserved 0950-9232/06 $30.00 www.nature.com/onc REVIEW pRb2/p130: a new candidate for retinoblastoma tumor formation G De Falco1,2 and A Giordano1,2 1Department of Human Pathology and Oncology, University of Siena, Siena, Italy and 2Sbarro Institute for Cancer Research and Molecular Medicine, College of Science & Technology Temple University, Philadelphia, PA 19122, USA Retinoblastoma is the most common primary intraocular alterations of tumor suppressor genes and proto- tumor in childhood. Mutations in both the alleles of the oncogenes that mayoccur if genomic integrityis RB1 gene represent the causative agent for the tumor to compromised owing to intrinsic factors or exogenous occur. It is becoming evident that, although these altera- agents. The mechanisms of inactivation of tumor tions represent key events in the genesis of retinoblastoma, suppressor genes and proto-oncogenes are different: they are not sufficient per se for the tumor to develop, and tumor suppressors are inactivated by‘loss of function other additional genetic or epigenetic alterations must mutations’, whereas proto-oncogenes are activated occur. A supportive role in the genesis of retinoblastoma through ‘gain of function mutations’. Tumor suppres- has recently been proposed for the RB1-related gene RB2/ sors are functionallyinactive in cancer cells, thus p130. Additionally, several other genetic alterations invol- determining the loss of control over cell proliferation; ving different chromosomes have been described as relevant on the other hand, proto-oncogenes are constitutively in the tumorigenic process. In this review we will analyse activated, leading to continuous signaling which acts current knowledge about the molecular mechanisms positivelyon cell growth.
    [Show full text]
  • Autism Genetics: Searching for Specificity and Convergence
    Berg and Geschwind Genome Biology 2012, 13:247 http://genomebiology.com/2012/13/7/247 REVIEW Autism genetics: searching for specicity and convergence Jamee M Berg1,2,3 and Daniel H Geschwind2,3,4* children has an ASD, representing a 78% increase over Abstract the past 6 years [7]. is drastic increase is most likely Advances in genetics and genomics have improved due to sociocultural factors rather than biological factors, our understanding of autism spectrum disorders. As including age at diagnosis, changing diagnostic criteria, many genes have been implicated, we look to points and broader inclusion rates, although genetic and of convergence among these genes across biological environ mental factors cannot be ruled out [8-11]. systems to better understand and treat these disorders. ASDs have a large genetic component. Concordance rates among monozygotic twins, dizygotic twins, and siblings are 50-90%, 0-30%, and 3-26%, respectively, Autism spectrum disorders (ASDs) are a group of neuro- supporting a major genetic contribution [12-14]. Interest- psychiatric disorders that include autism, pervasive ingly, the risk of ASD in second-born male siblings is develop mental disorder not otherwise specified (PDD- threefold that in second-born females, supporting NOS), and Asperger’s syndrome [1]. First described in models of reduced penetrance in females [14,15]. More- 1943, their diagnostic features continue to evolve based over, a recent study found a roughly twofold greater ASD on an expanding clinical and biological understanding concordance among full siblings than in half siblings, [2]. A child is diagnosed with an ASD if he or she shows additionally supporting a genetic contribution and early childhood deficits in: social communication and heritability of greater than 50% [16].
    [Show full text]
  • 1 OSC028- Biology (Genetics) Credit Hours: 3-4 Semester Hours Pre
    OSC028- Biology (Genetics) Credit Hours: 3-4 Semester Hours Pre-Requisite: OSC003 (Biology I) or Equivalent General Course Description: This course explores general genetics problems and processes as they are experienced by all biological systems: the nature of genetic materials, transmission/patterns of inheritance, molecular biology of gene function, gene expression and regulation, genetic variation, evolution and population genetics, comparative genetics/methods and tools and genetics and bioethics. With the evolving nature of the field it is critical for a bioethics component to be embedded in this course. Lectures include a standard modern general biology genetics text designed for introductory biology genetics for science majors to provide a strong basis for learning. Student Learning Outcomes (SLOs) are aligned with the core concepts and competencies which have been identified as foundational for undergraduate biological genetics literacy by the Genetics Society of America. Core Concepts include: I. Nature of Genetic Materials II. Transmission/Patterns of Inheritance III. Molecular Biology of Gene Function IV. Gene Expression and Regulation V. Genetic Variation VI. Evolution Genetics VII. Comparative Genetics/Methods and Tools VIII. Genetics and Bioethics In order for a course to be approved for OSC028 - Biology (Genetics), all of the following must be met: 1) Student Learning Outcomes (SLOs) marked with an asterisk (*) are required. 2) A minimum of 70% of the Student Learning Outcomes, including essential outcomes marked with an asterisk (*), must be met. CORE CONCEPTS: I. NATURE OF GENETIC MATERIALS What are the nature, structure and function of genetic components found in different biological systems. 1 1. Compare the molecular nature and structure of genetic materials found in prokaryotic and eukaryotic cells as well as bacterial, animal and plant viruses.
    [Show full text]
  • Rare Variants in the Genetic Background Modulate the Expressivity of Neurodevelopmental Disorders
    bioRxiv preprint doi: https://doi.org/10.1101/257758; this version posted April 18, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. Rare variants in the genetic background modulate the expressivity of neurodevelopmental disorders Short title: The rare genetic background and expressivity of neurodevelopmental disorders Lucilla Pizzo, MS1, Matthew Jensen, BA1, Andrew Polyak, BS1,2, Jill A. Rosenfeld, MS3, Katrin Mannik, PhD4,5 Arjun Krishnan, PhD6,7, Elizabeth McCready, PhD8, Olivier Pichon, MD9, Cedric Le Caignec, MD, PhD 9,10, Anke Van Dijck, MD11, Kate Pope, MS12, Els Voorhoeve, PhD13, Jieun Yoon, BS1, Paweł Stankiewicz MD, PhD3, Sau Wai Cheung, PhD3, Damian Pazuchanics, BS1, Emily Huber, BS1, Vijay Kumar, MAS1, Rachel Kember, PhD14, Francesca Mari, MD, PhD15,16, Aurora Curró, PhD15,16, Lucia Castiglia, MD17, Ornella Galesi, MD17, Emanuela Avola, MD17, Teresa Mattina, MD18, Marco Fichera, MD18, Luana Mandarà, MD19, Marie Vincent, MD9, Mathilde Nizon, MD9, Sandra Mercier, MD9, Claire Bénéteau, MD9, Sophie Blesson, MD20, Dominique Martin-Coignard, MD21, Anne-Laure Mosca-Boidron, MD22, Jean-Hubert Caberg, PhD23, Maja Bucan, PhD14, Susan Zeesman, MD24, Małgorzata J.M. Nowaczyk, MD24, Mathilde Lefebvre, MD25, Laurence Faivre, MD26, Patrick Callier, MD22, Cindy Skinner, RN27, Boris Keren, MD28, Charles Perrine, MD28, Paolo Prontera, MD29, Nathalie Marle, MD22, Alessandra Renieri, MD, PhD15,16, Alexandre Reymond, PhD4, R. Frank Kooy, PhD11, Bertrand Isidor, MD, PhD9, Charles Schwartz, PhD27, Corrado Romano, MD17, Erik Sistermans, PhD13, David J.
    [Show full text]
  • Management of a Patient with Tuberous Sclerosis with Urological Clinical Manifestations
    medicina Case Report Management of a Patient with Tuberous Sclerosis with Urological Clinical Manifestations 1, 2, 2, Vlad Padureanu y , Octavian Dragoescu y, Victor Emanuel Stoenescu y, Rodica Padureanu 3,* , Ionica Pirici 4,*, Radu Cristian Cimpeanu 5, Dop Dalia 6, Alexandru Radu Mihailovici 7 and Paul Tomescu 2 1 Department of Internal Medicine, University of Medicine and Pharmacy Craiova, 200349 Craiova, Romania; [email protected] 2 Department of Urology, University of Medicine and Pharmacy Craiova, 200349 Craiova, Romania; [email protected] (O.D.); [email protected] (V.E.S.); [email protected] (P.T.) 3 Department of Biochemistry, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania 4 Department of Anatomy, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania 5 Student, University of Medicine and Pharmacy Craiova, 200349 Craiova, Romania; [email protected] 6 Department of Pediatrics, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania; [email protected] 7 Department of Cardiology, University of Medicine and Pharmacy Craiova, 200349 Craiova, Romania; [email protected] * Correspondence: [email protected] (R.P.); [email protected] (I.P.) All these authors contributed equally to this work. y Received: 8 June 2020; Accepted: 19 July 2020; Published: 23 July 2020 Abstract: The tuberous sclerosis complex (TSC) is highly variable as far as its clinical presentation is concerned. For the implementation of appropriate medical surveillance and treatment, an accurate diagnosis is compulsory. TSC may affect the heart, skin, kidneys, central nervous system (epileptic seizures and nodular intracranial tumors—tubers), bones, eyes, lungs, blood vessels and the gastrointestinal tract. The aim of this paper is to report renal manifestations as first clinical signs suggestive of TSC diagnosis.
    [Show full text]
  • This Trait Shows Variable Expressivity with Respect to the Extent of Blotching
    BIOLOGY 321 WINTER 2011 ANSWERS TO ASSIGNMENT SET #3 Answers to Questions in Text Chapter 2 NOTE ON 38: substitute dominant for mutant in part a of the question. 38 a. This would be an example of a haploinsufficient gene since one copy of the wild-type allele does NOT produce enough protein for normal function. You do not expect the mutation to be recessive. Note on 48: This trait shows variable expressivity with respect to the extent of blotching. When analyzing the data, a plant should be considered blotched even if there is limited amount of blotching Problem 73 1 Chapter 6 12. 22. 2 25. 26. NOTE on allele designations in answer to 26. An uppercase A is given to the mutant allele even though it is only incompletely dominant to the wildtype allele. Although this is sort of confusing it is not an unusual designation 3 28 63 4 Answers to Additional Study Problems Ì Problem 1 ABO blood group: A and B are codominant alleles, O is recessive to both. MN blood group: M and N are codominant alleles; therefore a blood group of N means the individual is homozygous for that allele. Rh+ is dominant to Rh -. Child 1 belongs to the husband; child 2 belongs to the lover; child 3 could be the progeny of either the husband or the lover. For child 1 and child 2, which genotypes are critical in excluding the husband or lover as the parent? Which genotypes are consistent with either being the parent? Ì Problem 2 pleiotropic (multiple traits affected) sex-influenced, variably expressed Ì Problem 3 Answer is d: Note transmission through unaffected female in IVth generation.
    [Show full text]